

Methotrexate, vinBLAStine, DOXOrubicin, CISplatin (MVAC) -14 Days Therapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Indicator
Locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium	C67	00333a	

**If a reimbursement indicator (e.g. ODMS, CDS¹) is not defined, the drug and its detailed indication have not been assessed through the formal HSE reimbursement process.*

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Methotrexate is administered on day 1 and vinBLAStine, DOXOrubicin and CISplatin on day 2 once every 14 days until disease progression or unacceptable toxicity develops.

Granulocyte-Colony stimulating factor (G-CSF) is administered on day 3, 4, 5, 6 & 7 of every 14 day cycle.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1	Methotrexate	30mg/m ²	IV Bolus		Every 14 days
2	2	^a VinBLAStine	3mg/m ²	IV infusion	50ml 0.9% NaCl over 15 min	Every 14 days
3	2	^b DOXOrubicin	30mg/m ²	IV Bolus		Every 14 days
4	2	^c CISplatin	70mg/m ²	IV infusion	500ml 0.9% NaCl over 60-120mins	Every 14 days

^aVinBLAStine is a neurotoxic chemotherapeutic agent. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer

^bLifetime cumulative dose of DOXOrubicin is 450mg/m²
In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors outlined below and to the age of the patient.ⁱⁱ

^c **Pre and post hydration therapy required for CISplatin**

See local hospital policy recommendations.

Suggested prehydration for CISplatin therapy:

1. Administer 10mmol magnesium sulphate (MgSO₄) ((+/-KCl 20mmol/L if indicated) in 1000mL sodium chloride 0.9% over 60 minutes.

Administer CISplatin as described above

Post hydration: Administer 1000 ml 0.9% NaCl over 60mins

Mannitol 10% may be used to as per local policy to induce diuresis, although there is no conclusive evidence that this is required. The routine use of furosemide to increase urine flow is not recommended unless there is evidence of fluid overload (4, 5).

ELIGIBILITY:

- Indications as above
- ECOG 0-1

NCCP Regimen: Methotrexate, VinBLAStine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 1 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p style="text-align: center;"><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

EXCLUSIONS:

- Hypersensitivity to methotrexate, vinBLASTine, DOXOrubicin, CISplatin or any of the excipients
- Congestive heart failure (LVEF < 50%) or other significant heart disease
- Moderate/severe renal impairment (creatinine clearance < 60 mL/min)
- Pregnancy and Lactation
- Pre existing neuropathies ≥ grade 2
- Significant hearing impairment/tinnitus

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

FBC, Renal and liver profile

ECG

MUGA or ECHO (LVEF > 50% to administer doxorubicin) if >65 years or if clinically indicated.

Audiology and creatinine clearance if clinically indicated

Regular tests:

FBC, Renal and liver profile prior to each cycle

If clinically indicated MUGA scan or ECG

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

Haematological:

Table 1: Dose modification for haematological toxicity

ANC (x10 ⁹ /L)		Platelets (x10 ⁹ /L)	Dose
≥1.5	and	≥100	100% Dose
<1.5	or	<100	Hold*
Febrile neutropenia or ANC < 0.5 for 5-7 days	or	Thrombocytopenic bleeding or platelets < 25	Hold *then 75% of previous dose
*Do not start a new cycles until ANC ≥1.5 x 10 ⁹ /L and platelets ≥100 x10 ⁹ /L			

NCCP Regimen: Methotrexate, VinBLASTine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 2 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Renal and Hepatic Impairment:

Table 2: Dose modifications in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment					
	Cr Cl (ml/min)	Dose	Bilirubin(micromol/L)		AST (Units)	Dose		
Methotrexate	>80	100%	<50	and	<180	100%		
	60	65%	51-85	or	>180	75%		
	45	50%	>85			CI		
	<30	CI						
vinBLASTine	No dose reduction necessary		Bilirubin(micromol/L)		AST/ALT(Units)	Dose		
			26-51	or	60-180	50%		
			>51	and	N	50%		
			>51	and	>180	Omit		
DOXOrubicin	No dose reduction required. Clinical decision in severe impairment.		Bilirubin (micromol/L)		Dose			
			20-51		50%			
			51-85		25%			
			>85		Omit			
			If AST 2-3 x normal, give 75% dose.					
			If AST >3x ULN, give 50% dose					
CISplatin	GFR (ml/min)	Dose	No dose reduction necessary					
	≥60	100%						
	45-59	75%						
	<45	Consider CARBOplatin						

Management of adverse events:

Table 3: Dose Modification of MVAC Therapy for Adverse Events

Adverse reactions	Recommended dose modification
Neurotoxicity	
Grade 2 present at start of next cycle	Reduce dose of CISplatin and vinBLASTine by 25% dose.
Grade 3	Discontinue CISplatin and vinBLASTine

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Day 1 Low (Methotrexate)

Day 2 High (**Refer to local policy**).

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE:

- Hydration prior and post CISplatin administration (**Reference local policy or see recommendations above**). Patient should be encouraged to drink large quantities of liquids for 24 hours after the CISplatin infusion to ensure adequate urine secretion.

NCCP Regimen: Methotrexate, VinBLASTine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 3 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

- Prophylactic laxatives may be required to prevent constipation related to the use of vinca alkaloids.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pleural effusion or ascites:** Methotrexate should be used with caution in patients with pleural effusions or ascites, as methotrexate may accumulate in third space fluid compartments.
- **Extravasation:** vinBLASStine is a vesicant. DOXOrubicin may cause pain and tissue necrosis if extravasated. (Refer to local extravasation guidelines).
- **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction.
- **Hypersensitivity:** Hypersensitivity reactions have been reported with CISplatin.
- **Renal Toxicity:** Nephrotoxicity is common with CISplatin. Strongly encourage oral hydration. If oral hydration is not possible (e.g. excessive nausea), IV hydration is indicated. Avoid nephrotoxic drugs such as aminoglycoside antibiotics where possible. Where treatment with nephrotoxic drugs must be used, monitor renal function.
- **Ototoxicity and sensory neural damage:** These are associated with CISplatin therapy. They should be assessed by history prior to each cycle

DRUG INTERACTIONS:

- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probenecid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Co-administration of CISplatin has been reported to cause higher plasma concentrations of vinBLASStine.
- Erythromycin may increase the toxicity of vinBLASStine.
- Concurrent administration of calcium channel blockers with DOXOrubicin should be avoided as they may decrease the clearance of DOXOrubicin.
- CISplatin may potentiate the nephrotoxic and ototoxic effects of loop diuretics and aminoglycosides so concurrent use should be avoided.
- Current drug interaction databases should be consulted for more information.

ATC CODE:

Methotrexate - L01BA01
 vinBLASStine - L01CA01
 DOXOrubicin - L01DB01

NCCP Regimen: Methotrexate, VinBLASStine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 4 of 6

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

CISplatin - L01XA01

REFERENCES:

1. Sternberg CN et al. Randomized Phase III trial of high-dose-intensity MVAC chemotherapy and recombinant G-CSF vs classic MVAC in advanced urothelial tract tumours : European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001;19(10):2638.
2. Sternberg CN, de Mulder P et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-54.
3. Russell SD, Blackwell KL, Lawrence J, et al, Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28:3416-3421.
4. Nephrotoxicity Associated with CISplatin EviQ ID: 184 v.3
<https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-prevention/184-nephrotoxicity-associated-with-CISplatin>
5. Portilla D et al. CISplatin nephrotoxicity. UptoDate Accessed Oct 2017
https://www.uptodate.com/contents/CISplatin-nephrotoxicity?source=search_result&search=CISplatin%20hydration&selectedTitle=1~150
6. Methotrexate Summary of Product Characteristics Accessed Dec 2017
Available at http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-005-003_22042013144145.pdf3.
7. Vinblastine Sulfate 1mg/ml Solution for Injection. Accessed Dec 2017. Available at http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-009-003_20012016143038.pdf
8. Doxorubicin HCl 50mg Powder for Solution for Injection. Summary of Product Characteristics. Accessed Dec 2017. Available at
9. http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-026-002_11062014102040.pdf
10. Cisplatin 1mg/ml Concentrate for Solution for Infusion. Summary of Product Characteristics Accessed Dec 2017. Available at http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0749-119-002_06062013115044.pdf

Version	Date	Amendment	Approved By
1	20/06/2016		Prof Maccon Keane
2	11/12/2017	Updated with new NCCP regimen format, updated with revised CISplatin hydration regimen recommendations	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: Methotrexate, VinBLAStine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 5 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

ⁱ ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

ⁱⁱ Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease
- concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.

NCCP Regimen: Methotrexate, VinBLASTine, DOXOrubicin and CISplatin (MVAC)-14 days Therapy	Published: 20/06/2016 Review: 11/12/2019	Version number: 2
Tumour Group: Genitourinary NCCP Regimen Code: 00333	ISMO Contributor: Prof Maccon Keane	Page 6 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		